HC Wainwright Research Analysts Cut Earnings Estimates for Inhibikase Therapeutics, Inc. (NYSE:IKT)

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Research analysts at HC Wainwright lowered their Q2 2024 earnings estimates for Inhibikase Therapeutics in a research report issued to clients and investors on Tuesday, May 21st. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.58) for the quarter, down from their prior forecast of ($0.37). HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($1.71) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.87) EPS, FY2025 earnings at ($1.47) EPS and FY2026 earnings at ($1.46) EPS.

Inhibikase Therapeutics Stock Performance

Shares of NYSE:IKT opened at $1.83 on Thursday. The firm has a market cap of $11.86 million, a PE ratio of -0.55 and a beta of 1.31. The firm’s fifty day moving average is $1.88 and its 200-day moving average is $1.78. Inhibikase Therapeutics has a 52 week low of $0.79 and a 52 week high of $4.35.

Inhibikase Therapeutics (NYSE:IKT) last issued its earnings results on Wednesday, March 27th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative return on equity of 147.03%.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.